Company intelligence
Rare Access Action Project (RAAP)
A non-profit advocating for solutions to rare disease patient access to health care on both Federal and State levels.
About Rare Access Action Project (RAAP)
Many rare disease patients believe that because they have coverage (commercial, Medicaid or Medicare) that they will be able to utilize the medicine or technology that was developed for their rare disease. Unfortunately, this is not always the case. After rounds of prior authorizations and appeals, patients are often left with uncertainty. Many advances have been made, with significant advances in rare disease treatment on the horizon. However, the health care system in the United States has been slow in making those advances available to patients. The Facts: -Rare diseases individually affect small numbers of patients, collectively they affect as many as 25 million Americans – making this a serious public health concern. -An orphan disease is defined as a condition that affects fewer than 200,000 people nationwide. -There are over 7,000 known rare diseases and over 50 percent of rare diseases affect children. -During the first 25 years of the Orphan Drug Act (passed in 1983), 326 new drugs were approved by the FDA and brought to market for all rare disease patients combined. -Rare diseases account for 35% of children’s deaths in the first year of life. RAAP began in 2017 as an ad hoc coalition of life sciences and patient stakeholders focused on advocating for solutions to rare disease access to health care. The organization has evolved and is now a non-profit that is engaged in ongoing initiatives on both the Federal and State levels. RAAP is committed to exploring policy solutions to address structural issues in access and coverage and will engage with research, public education, issue advocacy, and lobbying activities to shine a light on the challenges facing rare disease patients; and offer common sense solutions to them. Current Projects: -State Educational Partnership with NCSL -Medicare Part D -Medicare -State Reinsurance Project RAAP is led by Michael Eging - 25 years as a life sciences professional and 12 years advocating on rare disease issues.
Verified activity
Signals from Rare Access Action Project (RAAP)
12 published signals
Legal & Regulatory
Rare Access Action Project (RAAP) urges Congress to pass the Newborn Screening Saves Lives Reauthorization Act to protect federal programs supporting state screening efforts and the timely review of new conditions.
Reported by Rare Access Action Project (RAAP)
Research & Knowledge
Rare Access Action Project (RAAP) published an article by 340B Report and William Newton on the move of oversight of the program from HRSAgov to CMS by the Trump Administration.
Reported by William Sarraille
Legal & Regulatory
Rare Access Action Project (RAAP) noted that the HRSA Notice committing to Rebate Model 2.0 was released more than a month ago.
Reported by William Sarraille
Legal & Regulatory
Rare Access Action Project (RAAP) noted that no lawsuit has been filed challenging the HRSA Notice committing to Rebate Model 2.0 yet.
Reported by William Sarraille
Presence & Recognition
Rare Access Action Project (RAAP) hosted an Exhibit Hall Learning Hub during the 2026 National Conference of State Legislatures Legislative Summit in Chicago.
Reported by Rare Access Action Project (RAAP)
Legal & Regulatory
Rare Access Action Project (RAAP) noted that the resolution applied the voluntary disclosure protocol standard 1.5 multiplier to the actual damages.
Reported by William Sarraille
Legal & Regulatory
Rare Access Action Project (RAAP) noted that the U.S. Attorney for the Middle District of Florida announced the Villages Health resolution involving false diagnosis codes and increased payments from the Medicare Advantage program.
Reported by William Sarraille
Legal & Regulatory
Rare Access Action Project (RAAP) noted that the Centers for Medicare & Medicaid Services adjusts monthly capitated payments for managed care plans under Medicare Part C based on risk diagnoses.
Reported by William Sarraille
Legal & Regulatory
Rare Access Action Project (RAAP) noted that Villages Health filed a Chapter 11 bankruptcy petition approved by the bankruptcy court.
Reported by William Sarraille
Legal & Regulatory
Rare Access Action Project (RAAP) noted that Villages Health announced a $541.5M resolution following a voluntary disclosure in 2024.
Reported by William Sarraille
Legal & Regulatory
Rare Access Action Project (RAAP) noted that Humana, UnitedHealthcare, and BlueCross and BlueShield of Florida received diagnosis codes from Villages Health.
Reported by William Sarraille
Presence & Recognition
Rare Access Action Project (RAAP) hosted a policy breakfast during the 2026 NCSL Legislative Summit in Chicago focused on supporting innovation and rare disease patients in the states.
Reported by Rare Access Action Project (RAAP)